Skip to main content
Midas Edge

TuHURA Biosciences IncNV

For the period ended Sep 30, 2024. Filed Nov 14, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 14, 2024

HURA$1.66+1.8%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Item 6. Exhibits

The exhibits listed below are filed or furnished as part of this Quarterly Report on Form 10-Q.

EXHIBIT INDEX

Exhibit NumberDescription
31.1Certification of principal executive officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*
31.2Certification of principal financial officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*
32.1Certification of principal executive officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**
32.2Certification of principal financial officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**
EX-101.INSInline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document*
EX-101.SCHInline XBRL Taxonomy Extension Schema Document*
EX-101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document*
EX-101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document*
EX-101.LABInline XBRL Taxonomy Extension Label Linkbase Document*
EX-101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document*
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
  • Filed herewith

** The certification furnished in Exhibit 32.1 and Exhibit 32.2 hereto are deemed to accompany this Quarterly Report on Form 10-Q and will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, except to the extent that the registrant specifically incorporates it by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Kintara Therapeutics, Inc.
Date: November 14, 2024By:/s/ James A. Bianco
James A. Bianco
Chief Executive Officer (Principal Executive Officer)
Kintara Therapeutics, Inc.
Date: November 14, 2024By:/s/ Dan Dearborn
Dan Dearborn
Chief Financial Officer (Principal Financial and Accounting Officer)
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.